Combination metabolic therapy for diffuse midline glioma in children
Official title: Combination metabolic therapy for diffuse midline glioma
Funded at University of California, San Francisco · NIH-11378158 · Data updated 2026-11-12
A pediatric brain cancer study tests a combination metabolic approach to kill DMG tumor cells in kids.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | August 7, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,959,492 |
| NIH project number | 4R01CA292674-03 |
| Project ID | NIH-11378158 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are children with diffuse midline glioma or patients whose tumor biology shows the H3K27M mutation relevant to the study.
✕Less likely to help
Patients without DMG or without the specific metabolic targets may not benefit from this approach.
What this research studies
This grant funds research on diffuse midline glioma, an aggressive brain tumor in children, using models based on patient tumors and lab systems. Researchers focus on how the cancer reprograms metabolism and how blocking two metabolic enzymes can trigger tumor cell death. The study uses genetic tools and brain-penetrant compounds to test whether hitting these targets can shrink tumors in animal models and disrupt tumor growth. If successful, the work could point to new, targeted options for children with DMG. The project is led by UC San Francisco experts and aims to translate findings toward clinical testing.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted therapies that improve survival for children with DMG.
How similar studies have gone: Preclinical studies have shown that dual inhibition of G6PD and GLO1 can be effective in DMG models, with ongoing translational efforts.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Viswanath, Pavithra — University of California, San Francisco
- Study coordinator: Viswanath, Pavithra
Related research
Other NIH-funded projects on the same topics.
-
Next‑gen oncolytic virus therapy for glioblastoma targeting AKT and ERK
A new cancer therapy using an engineered oncolytic virus to fight glioblastoma by blocking AKT/ERK signals and boosting the body’s immune response, with potential to reduce seizures and improve quality of life.
-
Bone marrow immune cells and glioma progression in teens and young adults
A study in adolescents and young adults with brain tumors looks at how immune cells from bone marrow may influence the progression from low-grade to high-grade gliomas.
-
How RNA Splicing Might Shape Glioma Cell States and Therapy Response
A small NIH-funded project will study how alternative RNA splicing influences glioma cell identities and treatment resistance in patient-derived cells.
-
Liquid biopsy for monitoring high-grade glioma using patient-specific DNA junctions
A Mayo Clinic team tests a blood test that looks for unique tumor DNA pieces in glioblastoma patients to monitor disease without frequent scans.
-
Deciphering how a brain cell pH helper influences glioma growth
A study is exploring whether a brain cell pH regulator (Slc4a4) affects the growth and blood vessel changes of malignant glioma to identify new angles for treatment.
-
Predicting how gene therapy spreads in glioblastoma after surgery to improve treatment coverage
This project uses a gene therapy that helps radiation work better against glioblastoma and builds computer models to predict where the therapy reaches after surgical tumor removal.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.